NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
About
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e. g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety.
The NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) funds research organizations, academic institutions, and community-based entities seeking to develop and test behavior change interventions for dental, oral, and craniofacial conditions. This phased funding opportunity is ideal for research teams ready to conduct rigorous clinical trials addressing oral health disparities and improving patient outcomes. The program supports both planning and implementation phases: the UG3 phase (up to 2 years) enables scientific and operational planning, including feasibility studies, intervention manual development, and protocol refinement, while successful projects may transition to the UH3 implementation phase (up to 5 years) for full-scale clinical trial execution. Eligible applicants include HBCUs, Hispanic-serving institutions, tribal governments, faith-based organizations, and other underrepresented academic centers. This is an exceptional opportunity for researchers committed to evidence-based behavioral interventions in oral health, particularly those serving underserved populations or addressing health equity gaps in dental care.
Funding Facts
● Applications openDeadline
January 6, 2028
Award Amount
Up to $500K
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $500K
Deadline
2028-01-06
Grant Type
federal
Application Cycle
Single phased application (UG3/UH3); deadline January 6, 2028
Best For
Research institutions, academic medical centers, HBCUs, minority-serving institutions, and organizations developing behavioral health interventions for oral and craniofacial conditions
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)?
Eligible applicants include HBCUs (Historically Black Colleges and Universities), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, AANAPISISs (Asian American Native American Pacific Islander Serving Institutions), Indian/Native American Tribal Governments, faith-based organizations, community-based organizations, eligible federal agencies, and other research institutions. For complete current eligibility requirements and specific organizational classifications, visit the official NIDCR funding opportunity announcement on grants.nih.gov.
How much funding does NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) provide?
Funding amounts range up to $500,000, though specific award amounts may vary by application, research scope, and institution type. The exact funding available for each cycle and any cost-sharing requirements should be verified on the official NIDCR Notice of Funding Opportunity (NOFO).
How do I apply for NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)?
Applications must be submitted as a single UG3/UH3 application following the specific instructions in the NOFO. Applications are typically submitted through Grants.gov or the NIH eRA Commons system. The deadline for the current cycle is January 6, 2028. Visit the official NIDCR website or grants.nih.gov for detailed application instructions, required forms, and submission procedures.
What can NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) funding be used for?
UG3 funding supports planning activities including small-scale feasibility and acceptability studies of behavioral interventions, testing of study procedures, and preliminary intervention testing. Operational planning includes developing final clinical protocols, intervention manuals, data management systems, quality assurance tools, and safety monitoring procedures. Projects meeting scientific milestones may transition to UH3 funding for full clinical trial implementation lasting up to five years.
Last updated: July 5, 2026